Comparing the HLA B leader gene in people with and without psoriatic arthritis
Compares the HLA B leader gene between adults with psoriatic arthritis and healthy adults.
Plain-language title generated from the registry record
Registry title: HLA B Leader in Patients With Psoriatic Arthritis
Key facts
- Where
- Amiens, FranceSee the site
Where in France
- Chu Amiens PicardieAmiens, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire, Amiens
- Trial code
- NCT07718815
- Record updated
- 22 July 2026
- Original description
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.Read full original descriptionShow less
HLA B Leader in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.
Given this association, these diseases are classically regarded as disorders of adaptive immunity.
In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.
Inclusion: For the "Patient" group:; Patient over 18 years of age; Patient affiliated to a social security scheme; Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie; For the "control" group:; Individuals over 18 years of age; Individual affiliated to a social security scheme; Individual having agreed to participate in the study; Individuals with no inflammatory or autoimmune diseases.
Exclusion: Patient or control not understanding French; Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort; Patient or control objecting to participation in the study.